Teleflex Incorporated Announces Public Offering of $500 Million of Senior Notes
November 16 2017 - 8:00AM
Business Wire
Teleflex Incorporated (NYSE: TFX) (“Teleflex”) announced today
the registered public offering, subject to market and other
conditions, of $500.0 million aggregate principal amount of senior
notes due 2027 (the “Notes”). The interest rate and other terms of
the Notes will be determined at pricing.
The Notes will be guaranteed by each of Teleflex’s existing and
future wholly-owned domestic subsidiaries that is a guarantor or
other obligor under its credit agreement and by certain of
Teleflex’s other wholly-owned subsidiaries.
Teleflex intends to use the net proceeds from the offering to
repay approximately $491.2 million of borrowings under its
revolving credit facility.
J.P. Morgan, BofA Merrill Lynch and PNC Capital Markets LLC are
acting as joint book-running managers for this offering.
The Notes will be issued pursuant to an effective shelf
registration statement filed with the Securities and Exchange
Commission (“SEC”) on Form S-3, as amended. The offering is being
made only by means of a prospectus supplement and accompanying
prospectus. You may obtain these documents for free by visiting
EDGAR on the SEC website at www.sec.gov. Alternatively, copies may
also be obtained from J.P. Morgan Securities LLC by calling (866)
803-9204, from Merrill Lynch, Pierce, Fenner & Smith
Incorporated at 200 North College Street, 3rd Floor, Charlotte, NC
28255-0001 Attn: Prospectus Department or from PNC Capital Markets
LLC at 225 Fifth Avenue, Three PNC Plaza 10th Floor, Pittsburgh, PA
15222 or by calling (855) 881-0697. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy
the Notes, nor shall there be any sale of the Notes, in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such jurisdiction.
ABOUT TELEFLEX INCORPORATED
Teleflex is a global provider of medical technologies designed
to improve the health and quality of people’s lives. We apply
purpose driven innovation – a relentless pursuit of identifying
unmet clinical needs – to benefit patients and healthcare
providers. Our portfolio is diverse, with solutions in the fields
of vascular and interventional access, surgical, anesthesia,
cardiac care, urology, emergency medicine and respiratory care.
Teleflex employees worldwide are united in the understanding that
what we do every day makes a difference..
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch® and Weck® – trusted brands united by a common
sense of purpose.
CAUTION CONCERNING FORWARD-LOOKING INFORMATION
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management’s current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements. These risks and uncertainties are identified and
described in more detail in our prospectus supplement and
accompanying prospectus and our filings with the SEC, including our
Annual Report on Form 10-K filed with the SEC on February 23, 2017
and quarterly reports on Form 10-Q filed with the SEC on May 4,
2017, August 3, 2017 and November 2, 2017, which can be obtained on
the SEC’s website at http://www.sec.gov. We undertake no obligation
to publicly update or revise any forward-looking statements, except
as otherwise specifically stated by us or as required by law or
regulation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171116005786/en/
Teleflex IncorporatedJake ElguiczeTreasurer and Vice President,
Investor Relations610-948-2836
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024